This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
Invitrogen
other brands :
NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience
product type :
protein
product name :
Human RHBDD2 Synthetic Peptide
catalog :
PEP-0975
quantity :
50 ug
price :
US 167.00
product information
Product Type :
Peptide
Product Name :
Human RHBDD2 Synthetic Peptide
Catalog # :
PEP-0975
Quantity :
50 ug
Price :
US 167.00
Clonality :
Synthetic
Purity :
purified
Reactivity :
Human
Applications :
Blocking Assay: Assay-dependent, Control: Assay-dependent
Species :
Human
Storage :
-20 C
Description :
The Rhomboid family of proteins is made up of several widely conserved polytopic membrane serine proteases that play roles in growth and development. Little is known about the role of RHBDD2. Its overexpression in breast carcinoma appears to be an indicator of poor prognosis and may play a role in breast cancer progression. The related proteins RHBDD1 and RHBDD3 are both involved in the regulation of apoptosis, suggesting that RHBDD2 may also be involved in the modulation of apoptotic activity.
Format :
Liquid
Applications w/Dilutions :
Blocking Assay: Assay-dependent, Control: Assay-dependent
Aliases :
0610011L13Rik; AI480532; H_RG122E10.2a; H_RG122E10.2b; NPD007; Rhbdd2; Rhbdl7; rhomboid domain containing 2; rhomboid domain-containing protein 2; rhomboid, veinlet-like 7; rhomboid-like protein 7; upregulated during skeletal muscle growth 1; Usmg1; WUGSC:H_RG122E10.2a; WUGSC:H_RG122E10.2b
company information
Invitrogen
Thermo Fisher Scientific
81 Wyman Street
Waltham, MA USA 02451
https://www.thermofisher.com81 Wyman Street
Waltham, MA USA 02451
800-678-5599
headquarters: USA
questions and comments